Page last updated: 2024-09-04

canertinib and Ovarian Neoplasms

canertinib has been researched along with Ovarian Neoplasms in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (57.14)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chitcholtan, K; Garrill, A; Hassan, W; Sykes, P	1
Berger, W; Brünner-Kubath, C; Grunt, TW; Grusch, M; Marian, B; Saferding, V; Shabbir, W; Singer, CF; Valent, P; Wagner, R; Zielinski, CC	1
Kreeger, PK; Prasasya, RD; Vang, KZ	1
Baselga, J; Hammond, LA	1
Lorusso, PM	1
Campos, S; Charbonneau, C; Hamid, O; Hirte, H; Jordan, C; Kaldjian, EP; Lenehan, PF; Oza, A; Plante, M; Potkul, RK; Seiden, MV; Varterasian, ML	1
Brose, MS; Flaherty, KT	1

Reviews

3 review(s) available for canertinib and Ovarian Neoplasms

Article	Year
HER-targeted tyrosine-kinase inhibitors. Oncology, 2002, Volume: 63 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2	2002
Phase I studies of ZD1839 in patients with common solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2003
Her-2 targeted therapy: beyond breast cancer and trastuzumab. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2006

Trials

1 trial(s) available for canertinib and Ovarian Neoplasms

Article	Year
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Administration, Oral; Aged; Aged, 80 and over; Disease Progression; ErbB Receptors; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Ovarian Neoplasms; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome	2005

Article

Year

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

Topics: Administration, Oral; Aged; Aged, 80 and over; Disease Progression; ErbB Receptors; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Ovarian Neoplasms; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome

2005

Other Studies

3 other study(ies) available for canertinib and Ovarian Neoplasms

Article	Year
Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer letters, 2018, 04-28, Volume: 420 Topics: Ascitic Fluid; Cell Culture Techniques; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Models, Biological; Morpholines; Ovarian Neoplasms; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Sulfones; Tumor Cells, Cultured	2018
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast cancer research and treatment, 2011, Volume: 129, Issue:2 Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Humans; Imidazoles; Molecular Targeted Therapy; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection	2011
A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. Biotechnology and bioengineering, 2012, Volume: 109, Issue:1 Topics: Antineoplastic Agents; ErbB Receptors; Female; Humans; Models, Biological; Models, Statistical; Morpholines; Ovarian Neoplasms; Systems Biology	2012